Latest news
Loading news…
CeeNU® (Lomustine) from Bristol Myers Squibb
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down. New York, United States Founded 1887 public
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
CeeNU® (Lomustine) from Bristol Myers Squibb on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
CeeNU® (Lomustine) from Bristol Myers Squibb was acquired by Septa Pharmaceuticals in 2026.
Last Funding
Acquisitions
0
Monthly Visits
Contacts
0
Ticker
BMY
NYSE
About CeeNU® (Lomustine) from Bristol Myers Squibb
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Public
- Ticker
- BMY
- Exchange
- NYSE
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Founded
- 1887
- Operating status
- Active
- Company type
- public
- Org types
- company
- HQ
- New York, United States
Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
FAQs about CeeNU® (Lomustine) from Bristol Myers Squibb
People who checked this page also checked these
Browse the full Acquirezy directory.